MARKET

PLX

PLX

Protalix Biother
AMEX
1.150
+0.020
+1.77%
After Hours: 1.160 0 0.00% 16:07 04/19 EDT
OPEN
1.120
PREV CLOSE
1.130
HIGH
1.166
LOW
1.100
VOLUME
449.80K
TURNOVER
0
52 WEEK HIGH
3.550
52 WEEK LOW
1.090
MARKET CAP
84.01M
P/E (TTM)
11.41
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PLX last week (0408-0412)?
Weekly Report · 6d ago
Weekly Report: what happened at PLX last week (0401-0405)?
Weekly Report · 04/08 11:27
Weekly Report: what happened at PLX last week (0325-0329)?
Weekly Report · 04/01 11:24
Weekly Report: what happened at PLX last week (0318-0322)?
Weekly Report · 03/25 11:27
Weekly Report: what happened at PLX last week (0311-0315)?
Weekly Report · 03/18 11:25
Protalix BioTherapeutics Q4 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $10.49M Beat $5.80M Estimate
Protalix BioTherapeutics reports quarterly losses of $0.07 per share and sales of $10.49 million. The company missed the analyst consensus estimate of $5.80 million by 133.33%. The company reported quarterly losses for the same period last year.
Benzinga · 03/14 10:56
Protalix BioTherapeutics GAAP EPS of $0.09 misses by $0.01, revenue of $65.49M beats by $1.54M
Seeking Alpha · 03/14 10:51
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports financial results for the fiscal year ended December 31, 2023. The company received regulatory approvals of Elfabrio for the treatment of adult patients with Fabry disease. Company to host conference call and webcast today at 8:30 a.m. EDT.
PR Newswire · 03/14 10:50
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

Webull offers Protalix Biotherapeutics Inc stock information, including AMEX: PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.